doi:10.48130/targetome-0026-0049

[1]

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians 75:10−45

doi: 10.3322/caac.21871

[2]

Tempero M. 2017. Active systemic treatment of pancreatic cancer. Journal of the National Comprehensive Cancer Network 15:723−725

doi: 10.6004/jnccn.2017.0084

[3]

Hayat U, Croce PS, Saadeh A, Desai K, Appiah J, et al. 2025. Current and emerging treatment options for pancreatic cancer: a comprehensive review. Journal of Clinical Medicine 14:1129

doi: 10.3390/jcm14041129

[4]

van Goor IWJM, Schouten TJ, Verburg DN, Besselink MG, Bonsing BA, et al. 2024. Predicting long-term disease-free survival after resection of pancreatic ductal adenocarcinoma: a nationwide cohort study. Annals of Surgery 279:132−137

doi: 10.1097/sla.0000000000006004

[5]

Ko AH, Malafa MP, Aguilera T, Al-Hawary MM, Basturk O, et al. 2025. Pancreatic adenocarcinoma, Version 4.2026. National comprehensive cancer network (NCCN) clinical practice guidelines in oncology. NCCN

[6]

Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. 2023. Pancreatic cancer: advances and challenges. Cell 186:1729−1754

doi: 10.1016/j.cell.2023.02.014

[7]

Springfeld C, Ferrone CR, Katz MHG, Philip PA, Hong TS, et al. 2023. Neoadjuvant therapy for pancreatic cancer. Nature Reviews Clinical Oncology 20:318−337

doi: 10.1038/s41571-023-00746-1

[8]

Wood LD, Canto MI, Jaffee EM, Simeone DM. 2022. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 163:386−402.e1

doi: 10.1053/j.gastro.2022.03.056

[9]

Dvorak HF. 2015. Tumors: wounds that do not heal − redux. Cancer Immunology Research 3:1−11

doi: 10.1158/2326-6066.cir-14-0209

[10]

Foster DS, Jones RE, Ransom RC, Longaker MT, Norton JA. 2018. The evolving relationship of wound healing and tumor stroma. JCI Insight 3:e99911

doi: 10.1172/jci.insight.99911

[11]

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, et al. 2019. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. Journal of Clinical Oncology 37:1062−1069

doi: 10.1200/jco.18.01295

[12]

Gunderson AJ, Yamazaki T, McCarty K, Phillips M, Alice A, et al. 2019. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. PLoS One 14:e0211117

doi: 10.1371/journal.pone.0211117

[13]

Gao Y, Chen S, Sun J, Su S, Yang D, et al. 2021. Traditional Chinese medicine may be further explored as candidate drugs for pancreatic cancer: a review. Phytotherapy Research 35:603−628

doi: 10.1002/ptr.6847

[14]

Ju Y, Xu D, Liao MM, Sun Y, Bao WD, et al. 2024. Barriers and opportunities in pancreatic cancer immunotherapy. npj Precision Oncology 8:199

doi: 10.1038/s41698-024-00681-z

[15]

Sherman MH, Beatty GL. 2023. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annual Review of Pathology: Mechanisms of Disease 18:123−148

doi: 10.1146/annurev-pathmechdis-031621-024600

[16]

Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, et al. 2014. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. British Journal of Cancer 111:1917−1923

doi: 10.1038/bjc.2014.495

[17]

Du Y, Zhao Y, Li J, Wang J, You S, et al. 2025. PLXDC1⁺ tumor-associated pancreatic stellate cells promote desmoplastic and immunosuppressive niche in pancreatic ductal adenocarcinoma. Advanced Science 12:2415756

doi: 10.1002/advs.202415756

[18]

Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, et al. 2019. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discovery 9:1102−1123

doi: 10.1158/2159-8290.cd-19-0094

[19]

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, et al. 2017. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. The Journal of Experimental Medicine 214:579−596

doi: 10.1084/jem.20162024

[20]

Tian C, Huang Y, Clauser KR, Rickelt S, Lau AN, et al. 2021. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells. Nature Communications 12:2328

doi: 10.1038/s41467-021-22490-9

[21]

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, et al. 2013. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62:112−120

doi: 10.1136/gutjnl-2012-302529

[22]

Shakiba M, Tuveson DA. 2025. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. Nature Immunology 26:678−691

doi: 10.1038/s41590-025-02134-6

[23]

Tian C, Clauser KR, Öhlund D, Rickelt S, Huang Y, et al. 2019. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proceedings of the National Academy of Sciences of the United States of America 116:19609−19618

doi: 10.1073/pnas.1908626116

[24]

Kung HC, Zheng KW, Zimmerman JW, Zheng L. 2025. The tumour microenvironment in pancreatic cancer − new clinical challenges, but more opportunities. Nature Reviews Clinical Oncology 22:969−995

doi: 10.1038/s41571-025-01077-z

[25]

Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, et al. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:822−835

doi: 10.1016/j.ccr.2012.04.025

[26]

Zhang J, Song J, Tang S, Zhao Y, Wang L, et al. 2023. Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation. Cell Reports 42:112620

doi: 10.1016/j.celrep.2023.112620

[27]

Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, et al. 2017. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47:323−338.e6

doi: 10.1016/j.immuni.2017.07.014

[28]

Blériot C, Dunsmore G, Alonso-Curbelo D, Ginhoux F. 2024. A temporal perspective for tumor-associated macrophage identities and functions. Cancer Cell 42:747−758

doi: 10.1016/j.ccell.2024.04.002

[29]

Giese MA, Hind LE, Huttenlocher A. 2019. Neutrophil plasticity in the tumor microenvironment. Blood 133:2159−2167

doi: 10.1182/blood-2018-11-844548

[30]

Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, et al. 2018. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Reports 23:3946−3959.e6

doi: 10.1016/j.celrep.2018.05.082

[31]

Ronchetti L, Boubaker NS, Barba M, Vici P, Gurtner A, et al. 2021. Neutrophil extracellular traps in cancer: not only catching microbes. Journal of Experimental & Clinical Cancer Research 40:231

doi: 10.1186/s13046-021-02036-z

[32]

Teijeira Á, Garasa S, Gato M, Alfaro C, Migueliz I, et al. 2020. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity 52:856−871.e8

doi: 10.1016/j.immuni.2020.03.001

[33]

Jin Y, Christenson ES, Zheng L, Li K. 2024. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies. Expert Review of Clinical Immunology 20:945−958

doi: 10.1080/1744666x.2024.2348605

[34]

Güngör N, Knaapen AM, Munnia A, Peluso M, Haenen GR, et al. 2010. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis 25:149−154

doi: 10.1093/mutage/gep053

[35]

Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, et al. 2019. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566:553−557

doi: 10.1038/s41586-019-0915-y

[36]

Rodríguez PC, Ochoa AC. 2008. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological Reviews 222:180−191

doi: 10.1111/j.1600-065x.2008.00608.x

[37]

Kemp SB, Pasca di Magliano M, Crawford HC. 2021. Myeloid cell mediated immune suppression in pancreatic cancer. Cellular and Molecular Gastroenterology and Hepatology 12:1531−1542

doi: 10.1016/j.jcmgh.2021.07.006

[38]

Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. The Journal of Immunology 181:5791−5802

doi: 10.4049/jimmunol.181.8.5791

[39]

Porta C, Consonni FM, Morlacchi S, Sangaletti S, Bleve A, et al. 2020. Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSCs. Cancer Research 80:2874−2888

doi: 10.1158/0008-5472.can-19-2843

[40]

Trovato R, Fiore A, Sartori S, Canè S, Giugno R, et al. 2019. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. Journal for ImmunoTherapy of Cancer 7:255

doi: 10.1186/s40425-019-0734-6

[41]

Mota Reyes C, Demir E, Çifcibaşı K, Istvanffy R, Friess H, et al. 2022. Regulatory T cells in pancreatic cancer: of mice and men. Cancers 14:4582

doi: 10.3390/cancers14194582

[42]

Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. 2024. Current and future immunotherapeutic approaches in pancreatic cancer treatment. Journal of Hematology & Oncology 17:40

doi: 10.1186/s13045-024-01561-6

[43]

Hiraoka N, Onozato K, Kosuge T, Hirohashi S. 2006. Prevalence of FOXP3⁺ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clinical Cancer Research 12:5423−5434

doi: 10.1158/1078-0432.ccr-06-0369

[44]

Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, et al. 2009. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunology 10:1000−1007

doi: 10.1038/ni.1774

[45]

Zhao J, Zhao J, Perlman S. 2012. Differential effects of IL-12 on tregs and non-treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS One 7:e46241

doi: 10.1371/journal.pone.0046241

[46]

Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, et al. 2012. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. Journal of Immunotherapy 35:629−640

doi: 10.1097/CJI.0b013e31826c8a4f

[47]

Peng YP, Xi CH, Zhu Y, Yin LD, Wei JS, et al. 2016. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Oncotarget 7:66586−66594

doi: 10.18632/oncotarget.11953

[48]

Huang Q, Huang M, Meng F, Sun R. 2019. Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment. Cellular & Molecular Immunology 16:87−89

doi: 10.1038/s41423-018-0014-2

[49]

Liu W, Yin B, Liang ZH, Yu Y, Lu N. 2022. Computed tomography perfusion imaging evaluation of angiogenesis in patients with pancreatic adenocarcinoma. World Journal of Clinical Cases 10:2393−2403

doi: 10.12998/wjcc.v10.i8.2393

[50]

An YF, Pu N, Jia JB, Wang WQ, Liu L. 2023. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: current dilemmas and future directions. Biochimica et Biophysica Acta (BBA) − Reviews on Cancer 1878:188958

doi: 10.1016/j.bbcan.2023.188958

[51]

Saiyin H, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, et al. 2015. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. The Journal of Pathology 236:142−154

doi: 10.1002/path.4506

[52]

Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. 2000. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. International Journal of Cancer 85:27−34

doi: 10.1002/(SICI)1097-0215(20000101)85:1<27::AID-IJC5>3.0.CO;2-8

[53]

Yuan H, Zhang Y, Liu F, Wu Y, Huang X, et al. 2025. Exploring the biological mechanism and clinical value of perineural invasion in pancreatic cancer. Cancer Letters 613:217515

doi: 10.1016/j.canlet.2025.217515

[54]

Chen SH, Zhang BY, Zhou B, Zhu CZ, Sun LQ, et al. 2019. Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche. American Journal of Cancer Research 9:1−21

[55]

Xue M, Zhu Y, Jiang Y, Han L, Shi M, et al. 2023. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Nature Communications 14:4600

doi: 10.1038/s41467-023-40314-w

[56]

Yang MW, Tao LY, Jiang YS, Yang JY, Huo YM, et al. 2020. Perineural invasion reprograms the immune microenvironment through cholinergic signaling in pancreatic ductal adenocarcinoma. Cancer Research 80:1991−2003

doi: 10.1158/0008-5472.can-19-2689

[57]

Banh RS, Biancur DE, Yamamoto K, Sohn ASW, Walters B, et al. 2020. Neurons release serine to support mRNA translation in pancreatic cancer. Cell 183:1202−1218. e25

doi: 10.1016/j.cell.2020.10.016

[58]

Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, et al. 2018. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discovery 8:403−416

doi: 10.1158/2159-8290.cd-17-1134

[59]

Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, et al. 2019. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 574:264−267

doi: 10.1038/s41586-019-1608-2

[60]

Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, et al. 2020. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368:973−980

doi: 10.1126/science.aay9189

[61]

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, et al. 2019. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178:795−806. e12

doi: 10.1016/j.cell.2019.07.008

[62]

Postler TS, Ghosh S. 2017. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metabolism 26:110−130

doi: 10.1016/j.cmet.2017.05.008

[63]

Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, et al. 2014. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769−1781

doi: 10.1136/gutjnl-2013-306271

[64]

Yang D, Sun X, Wang H, Wistuba II, Wang H, et al. 2025. TREM2 depletion in pancreatic cancer elicits pathogenic inflammation and accelerates tumor progression via enriching IL-1β⁺ macrophages. Gastroenterology 168:1153−1169

doi: 10.1053/j.gastro.2025.01.244

[65]

Esparza-Baquer A, Labiano I, Sharif O, Agirre-Lizaso A, Oakley F, et al. 2021. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut 70:1345−1361

doi: 10.1136/gutjnl-2019-319227

[66]

Thomas SK, Lee J, Beatty GL. 2020. Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. EBioMedicine 53:102662

doi: 10.1016/j.ebiom.2020.102662

[67]

Thiery JP, Acloque H, Huang RYJ, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139:871−890

doi: 10.1016/j.cell.2009.11.007

[68]

Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, et al. 2016. Metastatic progression is associated with dynamic changes in the local microenvironment. Nature Communications 7:12819

doi: 10.1038/ncomms12819

[69]

Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, et al. 2019. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567:249−252

doi: 10.1038/s41586-019-1004-y

[70]

Katsuta E, Qi Q, Peng X, Hochwald SN, Yan L, et al. 2019. Pancreatic adenocarcinomas with mature blood vessels have better overall survival. Scientific Reports 9:1310

doi: 10.1038/s41598-018-37909-5

[71]

Joyce JA, Fearon DT. 2015. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74−80

doi: 10.1126/science.aaa6204

[72]

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, et al. 2018. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut 67:497−507

doi: 10.1136/gutjnl-2016-311954

[73]

Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, et al. 2017. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clinical Cancer Research 23:137−148

doi: 10.1158/1078-0432.ccr-16-0870

[74]

Vijayan D, Young A, Teng MWL, Smyth MJ. 2017. Targeting immunosuppressive adenosine in cancer. Nature Reviews Cancer 17:709−724

doi: 10.1038/nrc.2017.86

[75]

Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, et al. 2018. Targeting both tumour-associated CXCR2⁺ neutrophils and CCR2⁺ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67:1112−1123

doi: 10.1136/gutjnl-2017-313738

[76]

Al Alawi R, Alhamdani MSS, Hoheisel JD, Baqi Y. 2020. Antifibrotic and tumor microenvironment modulating effect of date palm fruit (Phoenix dactylifera L.) extracts in pancreatic cancer. Biomedicine & Pharmacotherapy 121:109522

doi: 10.1016/j.biopha.2019.109522

[77]

Xiao Y, Qin T, Sun L, Qian W, Li J, et al. 2020. Resveratrol ameliorates the malignant progression of pancreatic cancer by inhibiting hypoxia-induced pancreatic stellate cell activation. Cell Transplantation 29:0963689720929987

doi: 10.1177/0963689720929987

[78]

Yan B, Cheng L, Jiang Z, Chen K, Zhou C, et al. 2018. Resveratrol inhibits ROS-promoted activation and glycolysis of pancreatic stellate cells via suppression of miR‐21. Oxidative Medicine and Cellular Longevity 2018:1346958

doi: 10.1155/2018/1346958

[79]

Tsang SW, Zhang H, Lin Z, Mu H, Bian ZX. 2015. Anti-fibrotic effect of trans-resveratrol on pancreatic stellate cells. Biomedicine & Pharmacotherapy 71:91−97

doi: 10.1016/j.biopha.2015.02.013

[80]

Chen Z, Chen LY, Wang P, Dai HY, Gao S, et al. 2012. Tumor microenvironment varies under different TCM ZHENG models and correlates with treatment response to herbal medicine. Evidence-Based Complementary and Alternative Medicine 2012:635702

doi: 10.1155/2012/635702

[81]

Feng J, Xu M, Wang J, Zhou S, Liu Y, et al. 2020. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Biomaterials 241:119907

doi: 10.1016/j.biomaterials.2020.119907

[82]

Wang Q, Qu C, Xie F, Chen L, Liu L, et al. 2017. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. American Journal of Cancer Research 7:125−133

[83]

Zhou X, Zhang P, Liu N, Zhang X, Lv H, et al. 2023. Enhancing chemotherapy for pancreatic cancer through efficient and sustained tumor microenvironment remodeling with a fibroblast-targeted nanosystem. Journal of Controlled Release 361:161−177

doi: 10.1016/j.jconrel.2023.07.061

[84]

Wang Y, Zhang A, Li Q, Liu C. 2024. Modulating pancreatic cancer microenvironment: the efficacy of Huachansu in mouse models via TGF-β/Smad pathway. Journal of Ethnopharmacology 326:117872

doi: 10.1016/j.jep.2024.117872

[85]

Yan D, Jiang Y, Hu Y, Hu Z, Feng H, et al. 2026. Dahuang Zhechong pill combined with TNS4 silencing inhibits the NF-κb/VEGF pathway to slow down the progression of pancreatic cancer. Recent Patents on Anti-Cancer Drug Discovery 21:211−223

doi: 10.2174/0115748928379439250621171215

[86]

Choi HS, Lee K, Kim MK, Lee KM, Shin YC, et al. 2016. DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis. Oncotarget 7:21775−21785

doi: 10.18632/oncotarget.7982

[87]

Qiao Y, Yan LJ, Yan C. 2020. Sauchinone inhibits hypoxia-induced epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma cells through the Wnt/β-catenin pathway. Anti-Cancer Drugs 31:918−924

doi: 10.1097/cad.0000000000000956

[88]

Chen H, Zhang J, Luo J, Lai F, Wang Z, et al. 2013. Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-κB-mediated VEGF signaling pathway. Oncology Reports 30:589−595

doi: 10.3892/or.2013.2529

[89]

Prasad S, Yadav VR, Sung B, Gupta SC, Tyagi AK, et al. 2016. Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. Oncotarget 7:13182−13196

doi: 10.18632/oncotarget.7537

[90]

Lin SZ, Xu JB, Ji XU, Chen HUI, Xu HT, et al. 2015. Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-β/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs. Molecular Medicine Reports 12:5865−5871

doi: 10.3892/mmr.2015.4158

[91]

Zhang J, Wang P, Ouyang H, Yin J, Liu A, et al. 2013. Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. PLoS One 8:e70334

doi: 10.1371/journal.pone.0070334

[92]

Wang Z, Zhou X, Guo Y, Zhang J, Liu Y, et al. 2026. Integrating network pharmacology and metabolomics to explore the mechanism of Xihuang Pill in exerting anti-tumor immune effects against pancreatic ductal adenocarcinoma. Journal of Ethnopharmacology 356:120788

doi: 10.1016/j.jep.2025.120788

[93]

Zhang Y, Ruan L, Li X, Si W, Yang P, et al. 2025. Modified sijunzi decoction inhibits pancreatic cancer progression and improves immune suppression: network pharmacology and experimental validation. Drug Design, Development and Therapy 19:8949−8966

doi: 10.2147/dddt.s520390

[94]

Wang B, Zheng X, Liu J, Zhang Z, Qiu C, et al. 2018. Osthole inhibits pancreatic cancer progression by directly exerting negative effects on cancer cells and attenuating tumor-infiltrating M2 macrophages. Journal of Pharmacological Sciences 137:290−298

doi: 10.1016/j.jphs.2018.07.007

[95]

Zheng X, Li D, Li J, Wang B, Zhang L, et al. 2019. Optimization of the process for purifying icariin from Herba Epimedii by macroporous resin and the regulatory role of icariin in the tumor immune microenvironment. Biomedicine & Pharmacotherapy 118:109275

doi: 10.1016/j.biopha.2019.109275

[96]

Liu X, Zhang H, Cao J, Zhuo Y, Jin J, et al. 2022. Isobavachalcone activates antitumor immunity on orthotopic pancreatic cancer model: a screening and validation. Frontiers in Pharmacology 13:919035

doi: 10.3389/fphar.2022.919035

[97]

Xu X, Cui L, Zhang L, Yang L, Zhuo Y, et al. 2023. Saikosaponin d modulates the polarization of tumor-associated macrophages by deactivating the PI3K/AKT/mTOR pathway in murine models of pancreatic cancer. International Immunopharmacology 122:110579

doi: 10.1016/j.intimp.2023.110579

[98]

Zhang C, Jiang X, Li Y, Liu F, Shen Q, et al. 2026. Pi Ji Pills reshape the pancreatic cancer immune microenvironment and enhance the efficacy of gemcitabine through dual mechanisms of PI3K/AKT pathway blockade and NETs inhibition. Journal of Ethnopharmacology 355:120579

doi: 10.1016/j.jep.2025.120579

[99]

Ikemoto T, Shimada M, Iwahashi S, Saito Y, Kanamoto M, et al. 2014. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. International Journal of Clinical Oncology 19:81−86

doi: 10.1007/s10147-013-0529-6

[100]

Hao C. 2023. Clinical efficacy of QYHJ and standard chemotherapy in the treatment of advanced pancreatic cancer. ClinicalTrials. gov. https://clinicaltrials.gov/study/NCT05840341